JP Patent

JP2019518022A — 肝内胆汁うっ滞性疾患の処置

Assigned to CymaBay Therapeutics Inc · Expires 2019-06-27 · 7y expired

What this patent protects

セラデルパルまたはその塩での治療による肝内胆汁うっ滞性疾患の処置。

USPTO Abstract

セラデルパルまたはその塩での治療による肝内胆汁うっ滞性疾患の処置。

Drugs covered by this patent

seladelpar-lysine (SELADELPAR LYSINE)

Patent Metadata

Patent number: JP2019518022A
Jurisdiction: JP
Classification: —
Expires: 2019-06-27
Drug substance claim: No
Drug product claim: No
Assignee: CymaBay Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.